Related Experiment Video
Updated: Jul 16, 2026
11:12
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study
Maïa Chanrion1, Hélène Fontaine, Carmen Rodriguez
1INSERM U868, Cancer Research Centre, CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France. mboulfroy@valdorel.fnclcc.fr <mboulfroy@valdorel.fnclcc.fr>
BMC Cancer
|March 7, 2007
Summary
Molecular profiling of 47 genes in breast tumors identified a novel subgroup (subgroup 7) with a low recurrence rate. This gene expression analysis offers a new way to classify breast cancer subtypes and predict outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Breast cancer heterogeneity complicates prognosis using traditional histopathology.
- Molecular profiling offers potential for improved tumor classification and outcome prediction.
Purpose of the Study:
- To classify breast tumors using gene expression profiling.
- To identify molecular signatures predictive of clinical behavior.
Main Methods:
- Quantitative RT-PCR was used to analyze RNA expression of 47 genes in 199 primary breast tumors.
- Unsupervised hierarchical clustering and Chi2 analysis were employed for subgroup identification and signature definition.
- Validation was performed on an independent tumor set using defined molecular signatures.
Main Results:
- Gene expression analysis revealed distinct tumor subgroups, including potential new subtypes.
- Specific molecular signatures were identified for certain subgroups, validated on an external dataset.
- A novel subgroup (subgroup 7) was identified, characterized by specific bioclinical features and a low 5-year recurrence rate.
Conclusions:
- Gene expression profiling of 47 genes classified breast tumors into molecular subgroups.
- Subgroup 7 exhibits favorable bioclinical features, notably a reduced recurrence rate.
- Gene expression profiling may uncover novel breast cancer subclasses with distinct molecular signatures and clinical behaviors, warranting further validation.